Expert Interview
A 2nd View: Discussing the Phase 1/2 data from Incyte’s monoclonal antibody, INCA033989, in patients with mutant calreticulin -expressing myeloproliferative neoplasms
Ticker(s): INCYInstitution: Washington University St. Louis
- Professor Department of Medicine Oncology Division Bone Marrow Transplantation & Leukemia at WUSTL
- Currently treats ~300 patients with multiple myeloma, 25 patients with AML, 10 patients with CMML, and ~15 patients per month with AL Amyloidosis.
- Clinical research focus on strategies to improve the outcome of patients with multiple myeloma, acute myeloid leukemia, and myelodysplastic syndromes.
What are your impressions of the safety and efficacy signals observed in the dose escalation phase of INCA033989, particularly in the context of high-risk essential thrombocythemia patients resistant or intolerant to prior cytoreductive therapy?
Added By: sara_adminHow promising do you find the strategy of targeting mutant calreticulin directly with a monoclonal antibody, and what advantages might this offer compared to existing JAK inhibitors in MPNs?
Added By: sara_adminWhat additional data or endpoints would you need to see in order to consider INCA033989 a viable addition to the MPN treatment landscape?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
